Oxurion NV — Major Shareholding Notification 2024

Jul 18, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

July 18, 2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Oxurion received a transparency notification on July 17, 2024, from Atlas Special Opportunities, LLC indicating that as of July 17, 2024, it held 941,611,204 shares of the then outstanding 12,275,690,851 shares, and therefore crossed below the threshold (10%) by virtue of the sale of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
Pascal.ghoson@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

________

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION ldentification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights	+
4) Notification by
A person that notifies alone	+
5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)
		+
Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6 persons referred to in Sections 5 and 6	Part II

7) Date on which the threshold is crossed

8) Threshold that is crossed (in %)

10

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

12,275,690,851 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	1,785,024,954	941,611,204		7 67%
TOTAL		941,611,204	o	7.67%	0.00%

+

Start with "groups" of holders. Add subtotlas with 2, and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or l

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL			0	0.00%

The totals will be updated once you have clicked on

TOTAL (A & B)		# of voting rights % of voting rights
	CALCULATE	941.611.204	7.67%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

			(DD/MM/YYYY)
Holder	will cease to hold / will hold again	voting rights as of
13) Additional information

On 6 June 2024 (with setlement date on 7 June 2024), Alass Special Oportunities LC sold 17686, 14 stareholding decreased of 1,008, (59,811 stares (-
13.10%, denominator = 12.275,690,851).
On " June 2024 (with settenent date on 1 June 2024, Must and 0,224, 440 shares in Ourin N. as a result of which its stareholding becreased o 1,547,85,37 shares (=
12.61%, denominator = 12,275,690,851).
On 14 June 2024 (with setternent date on 15 June 2020) 45 200000 stare in Oxinon NV, as a result of which its shareholding decreased or 502,95,37 shares (-
12.24%, denominator = 12,275,690,851).
On 4 July 2024 with settenent date on 3 July 21, Atas Special Courner in Curino NV, as a result of this is stares of 1, 13, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20
denominator = 12.275.690.851).
On 9 July 2024 with setterner date on 1 July 2009,000 stares in Quinn N. as result which is starending decreased of 30,711,220 stares = 10,4%
denominator = 12,275,690,851).
On 15 July 2024 with settement date on 17 July 2021, Nas Special Courion NY, as a result of which its stareholding decreased b 91,611,204 shares (=1.6%,
denominator = 12,275,690,851).

Signature	Patrick Varice
	For security reasons, the unsigned form in xlsx format should be transmitted to trp.fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.
	In addition, a signed copy in PDF format should also be transmitted.

Attachment

• NL